Brochure
19 May 2023

Sustainability at Midas Pharma

PDF 558 kB

For Midas as a family owned company, Health, Safety, Environment and Ethics are important factors to assure a sustainable business in the future. Each and every one of us is responsible to protect our environment, our people and our customers. In order to make sure that HSE related activities have a secular effect we have summarized our commitments with respect to Health, Safety, Environment, Community, Quality and Ethics in Our Credo. 

Content provided by our supplier

Midas

  • Country/Region:
    Germany
  • On CPHI since:
    2015
  • Certificates:
    1
  • Employees:
    250 - 499
Company types
Consultancy
Contract Service
Drug delivery device Supplier/Manufacturer
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
API Producer
Biopharmaceutical
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
End-product distributor (Wholesale)
Fine Chemicals Company
Generic APIs producer
Intermediates Manufacturer
Marketing Services Provider
Medical Devices
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Supply Chain
Technology

Other Content from Midas (3)

  • News Sustainability at Midas Pharma

    For Midas as a family owned company, Health, Safety, Environment and Ethics are important factors to assure a sustainable business in the future. Each and every one of us is responsible to protect our environment, our people and our customers. We also encourage our suppliers to share our values and to support us in achieving our sustainability goals.
  • News MIdas Biopharma

    Our expertise – your benefit:With more than 35 years of experience, Midas Pharma brings proven expertise to every stage of the biopharmaceutical product life cycle.
  • News Biofidus AG is now a member of the Midas Group

    With the acquisition of Biofidus, a leading provider of structural and functional characterization of biopharmaceuticals, Midas Pharma has taken a major step forward in expanding its portfolio of biopharmaceutical services.